Improvement in Suicidal Ideation after Ketamine Infusion:
Relationship to Reductions in Depression and Anxiety

Elizabeth D. Ballard, Ph.D.,a Dawn F. Ionescu, M.D.a, Jennifer L. Vande Voort, M.D.a, Mark J. Niciu, M.D., Ph.D.a, Erica M. Richards, M.D., Ph.D.a, David A. Luckenbaugh, M.A.b, Nancy E. Brutsche, M.S.N.a, Rezvan Ameli, Ph.D.a, Maura Furey, Ph.D.a, and Carlos A. Zarate Jr., M.D.a

aExperimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, 20892

Abstract

Objective—Suicide is a psychiatric emergency. Currently, there are no approved pharmacologic treatments for suicidal ideation. Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that rapidly reduces suicidal ideation as well as depression and anxiety, but the dynamic between these symptoms is not known. The aim of this analysis was to evaluate whether ketamine has an impact on suicidal thoughts, independent of depressive and anxiety symptoms.

Address correspondence to: Elizabeth D. Ballard, Ph.D., Building 10, CRC Room 7-5541, 10 Center Drive, MSC 1282, Bethesda, MD 20892, Phone: (001) 301-435-9399, Fax: (001) 301-402-9360, Elizabeth.Ballard@nih.gov. Presented as a Poster at the American Psychopathological Association, New York City, March 6–8, 2014

Conflict of Interest

Dr. Furey is listed as a co-inventor on a patent application for the use of scopolamine in major depression and Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Drs. Furey and Zarate have assigned their rights in the patent to the U.S. Government but will share a percentage of any royalties that may be received by the Government. The remaining authors have no conflicts of interest to disclose, financial or otherwise.

Contributors: All authors contributed to manuscript writing or data analysis, and agreed to submit the final version for publication.

Dr. Ballard conceptualized the study design, completed and interpreted the statistical analysis, drafted the manuscript and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Dr. Ionescu assisted in the conceptualization of the study design, assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Dr. Vande Voort assisted in the conceptualization of the study design, assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Dr. Niciu assisted in the conceptualization of the study design, assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. He approved the final manuscript before submission.

Dr. Richards assisted in the conceptualization of the study design, assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Mr. Luckenbaugh assisted in the statistical design, analysis and interpretation and edited the manuscript for intellectual content. He approved the final manuscript before submission.

Ms. Brutsche assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Dr. Ameli assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Dr. Furey assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. She approved the final manuscript before submission.

Dr. Zarate provided research supervision, assisted in the conceptualization of the study design, assisted in the interpretation of the statistical analysis and edited the manuscript for intellectual content. He approved the final manuscript before submission.

Publisher’s Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Methods—133 patients with treatment-resistant depression (major depressive disorder or bipolar I/II disorder) received a single subanesthetic infusion of ketamine (0.5mg/kg over 40 minutes). Post-hoc correlations and linear mixed models evaluated the relationship between suicidal ideation and depression and anxiety symptoms using the Hamilton Depression Rating Scale (HAM-D), Scale for Suicidal Ideation (SSI), Beck Depression Inventory (BDI), and Hamilton Anxiety Rating Scale (HAMA) focusing on 230 minutes post-infusion.

Results—At 230 minutes post-infusion, correlations between changes in suicidal ideation and depression ranged from 0.23 to 0.44 (p < .05), accounting for up to 19% in the variance of ideation change. Correlations with anxiety ranged from 0.23 to 0.40 (p < .05), accounting for similar levels of variance. Ketamine infusion was associated with significant reductions in suicidal ideation compared to placebo, when controlling for the effects of ketamine on depression (F(1,587)= 10.31, p = .001) and anxiety (F(1,567)= 8.54, p = .004).

Conclusions—Improvements in suicidal ideation after ketamine infusion are related to, but not completely driven by, improvements in depression and anxiety. Investigation of the specific effects of ketamine on suicidal thoughts is warranted.

Keywords
Ketamine; Suicide; Depression; Suicidal Ideation

Introduction
Suicidal ideation is a frequent and potentially life-threatening indication for psychiatric emergency services (Ting et al., 2012). Over 38,000 Americans died by suicide in 2010 (bCenters for Disease Control and Prevention, 2013b), and it is estimated that many of these individuals were currently depressed or had a history of an affective disorder (aCenters for Disease Control and Prevention, 2013a; Conwell et al., 1996). Due to the known relationship between suicidal ideation and attempts/death (Baca-Garcia et al., 2011), effective interventions are a priority, as highlighted by the 2012 U.S. National Strategy for Suicide Prevention (2012). Unfortunately, few psychiatric medications have been shown to reduce suicidal ideation as compared to the anti-aggressive and anti-impulsive effects of lithium and clozapine (Frogley et al., 2012; Hennen and Baldessarini, 2005; Quiroz et al., 2010), which may be more suited to reducing suicide attempts than suicidal ideation. Additionally, available antidepressants may take weeks-to-months to achieve the desired effects. As a consequence, the 400,000 individuals who seek emergency treatment for suicidal thoughts and behavior each year often do not receive timely relief (Ting et al., 2012).

Novel, rapid-acting antidepressants hold great potential in the emergent treatment of suicidal patients. Ketamine is a glutamatergic, N-methyl-D-aspartate (NMDA) receptor antagonist that has rapid-acting antidepressant effects (Berman et al., 2000; Diazgranados et al., 2010b; Ibrahim et al., 2012; Zarate et al., 2006) in both unipolar and bipolar depressed patients. A single subanesthetic dose (0.5mg/kg over 40 minutes) of ketamine has antidepressant efficacy within hours-to-days with concomitant reductions in suicidal ideation on a similar time frame. In an open label trial of patients with Major Depressive Disorder (MDD), symptoms including suicidal ideation, anxiety and hopeless thoughts dissipated after a single
infusion (DiazGranados et al., 2010a). Ketamine has also been shown to reduce implicit measures of suicidal cognition in both single and repeated-dose paradigms (Price et al., 2014; Price et al. 2009). Naturalistic studies and case reports in emergency department settings have also demonstrated reduced suicidal ideation after ketamine infusion (Larkin and Beutrais, 2011; Zigman and Blier, 2013).

As the evidence base for ketamine’s anti-suicidal properties continues to grow, a critical question emerges: how does ketamine reduce suicidal thoughts? Suicidal ideation has a demonstrated relationship to both depression and anxiety symptoms and diagnoses (Nock et al., 2010; Rappaport et al., 2013; Sareen et al., 2005). Since ketamine has been shown to reduce both depression and anxiety (Diazgranados et al., 2010b; Ibrahim et al., 2012; Irwin et al., 2013; Zarate et al., 2006), a simple explanation may be that ketamine reduces suicidal thoughts through its impact on these symptoms. In support of this perspective, a re-analysis of 9185 patients across several randomized clinical trials of fluoxetine and venlafaxine found that depression mediated the reductions in suicidal thoughts and behaviors in adults, but not adolescents (Gibbons et al., 2012). Similarly, a recent analysis of ketamine in patients with treatment-resistant depression found that reductions in depressive symptoms mediated the reductions in suicide ideation after infusion (Price et al., 2014).

However, not all suicidal ideation and behavior are explained by mood and anxiety symptoms alone. Many individuals think about, attempt and die by suicide outside the context of a depressive or anxious episode (aCenters for Disease Control and Prevention, 2013a; Conwell et al., 1996). Furthermore, a meta-analyses of psychotherapy for depression has found inconclusive effects of these therapies on suicidal thoughts and behaviors (Cuijpers et al., 2013), leading to the development of suicide-focused psychotherapies, such as Cognitive Behavioral Therapy for Suicidal Patients (Brown et al., 2005b). It is possible that ketamine decreases suicidal thoughts independently from depression and anxiety. If ketamine is found to impact suicidal thoughts directly, this would have important implications for both the neurobiological profile of suicidal thoughts and the treatment of suicidal patients.

This analysis takes advantage of the history of ketamine research conducted by our group to evaluate the relationship between suicidal ideation, depression and anxiety in a sample of depressed patients. We hypothesized that reductions in suicidal ideation post-infusion would be independent of reductions in depression and anxiety symptoms. To this end, we evaluated changes in ideation post-infusion. We also evaluated the effect of ketamine on suicidal thoughts when controlling for depressive symptoms and anxiety symptoms. Lastly, we identified whether ketamine had an impact on two cognitive aspects of suicidal ideation: the wish to live and the wish to die.

Methods

Patient-level data was obtained from four independent, previously-published clinical trials, including one open-label trial and one ongoing mechanism of action clinical trial, investigating the use of ketamine in treatment-resistant MDD and bipolar disorder (BD) depression without psychotic features (Diazgranados et al, 2010b, Ibrahim et al., 2012;
Patients 18–65 years old were admitted to the inpatient unit at the NIMH Mood and Anxiety Disorders Research Program in Bethesda, MD, USA. All participants provided written informed consent as approved by the NIH Combined Central Nervous System (CNS) Institutional Review Board. Patients were experiencing a major depressive episode of at least moderate severity [objectively defined as ≥18 on the 21-item Hamilton Depression Rating Scale (HAMD) (Zarate et al., 2006), or ≥20 or ≥22 on the Montgomery-Asberg Depression Rating Scale (MADRS) (Diazgranados et al., 2010b; Zarate et al., 2012)] at screening and at the start of each infusion. In addition, all patients met DSM-IV criteria for either MDD or BD in a depressive episode based on clinical assessment and the Structured Clinical Interview for Axis I Diagnostic and Statistical Manual (DSM)–IV Disorders, patient version (SCID-P) (First et al., 2001). No active substance use disorder diagnoses (except nicotine and caffeine) were permitted in the three months prior to screening. Patients were in generally good physical health as determined by clinical history, physical examination and/or laboratory assessments.

A single subanesthetic (0.5mg/kg) dose of ketamine hydrochloride was administered intravenously over 40 minutes. Patients were assessed on a variety of clinician-administered and self-reported psychiatric measures, as described below, at 60 minutes before and at 40, 80, 120, 230 minutes and one, two and three days following the ketamine infusion.

**Measures**

The *Hamilton Rating Scale for Depression* (HAMD) is a 17-item clinician-administered scale used to assess depression severity (Hamilton, 1960). Ratings are made on the scale from 0–4; there is one item that specifically assesses suicidal ideation and propensity for suicidal behavior. This suicide item was used as the criterion in this analysis as it was administered to all patients in this sample (n = 133) and has been correlated with other measures of suicidal thoughts (Desseilles et al., 2012). The Anxiety Somatization Factor Score is a sub-score of the HAMD that is used to assess anxious features of depression via the following six items: psychic anxiety, somatic anxiety, general somatic symptoms, gastrointestinal symptoms, hypochondriasis, and insight. This score was previously derived from a factor analysis of the HAMD (Cleary and Guy, 1977), and has been deemed useful for studying anxiety within depression for both research and clinical purposes (McClintock et al., 2011). Patients scoring ≥7 on this subscale have been found to have higher levels of suicidal thoughts and behaviors (Fava et al., 2006).

The *Scale for Suicide Ideation* (SSI) is a 19-item, clinician-administered measure of current suicidal thinking (Beck et al., 1979). Patients are administered the first 5 items; if they endorse any desire to make a suicide attempt or passive suicidal ideation, they are administered the remaining 14 items. Scores from the SSI reported in this analysis are limited to the first two items, the “Wish to Live” and “Wish To Die” items, which have been found to predict later suicide (Brown et al., 2005a). The SSI was administered to a subset (n = 106) of the participating patients.

The *Beck Depression Inventory* (BDI) is a 19-item self-reported measure of depression severity (Beck et al., 1961). Each item is measured on a scale of 0–3 and there was one item
assessing suicidal thoughts which was excluded from total score for the purposes of this analysis.

The Hamilton Psychiatric Rating Scale for Anxiety (HAMA) is a 14-item clinician-administered measure of anxiety severity (Hamilton, 1959). Each item is rated on a scale of 0 to 4.

**Statistical Analysis**

To evaluate the relationship between changes in ideation, depression and anxiety, a series of Pearson correlations evaluated absolute change in symptoms at 230 minutes post-infusion. This time point was chosen as previous analyses have demonstrated that suicidal ideation decreases in the first four hours after ketamine infusion (DiazGranados et al., 2010a). Suicidal ideation, depression and anxiety were each evaluated across two scales to address potential differences in symptom change across assessment type. When correlating ideation to either of the depression rating scales (HAMD or BDI), suicide items were removed from the total score to reduce redundancy. Also, because the Anxiety Somatization Factor Score was created from the HAMD, these items were removed when assessing for depression.

A series of linear mixed models were conducted in a subset of patients (n = 57), who participated in double-blind, placebo-controlled, crossover studies of ketamine and had any suicidal thoughts at baseline (DiazGranados et al., 2010a; Zarate et al., 2012; Zarate et al., 2006). Time and intervention status were included as fixed within-subjects factors. A fixed intercept and the interaction between drug and time were also included. A compound symmetry covariance structure was used as prior analyses suggested this had the best fit according to Schwarz’s Bayesian criteria. The model was run to evaluate the effects of ketamine on suicide ideation alone controlling for baseline suicidal ideation and then a separate model controlling for ketamine’s effects on depression over time by including the three-way interaction of ketamine, depression and time. If the three-way interaction was not significant, it was excluded from the model and the two way interaction between depression and ketamine was included. A similar set of models were run with anxiety. As a final analysis, two linear mixed models were conducted to evaluate the effect of ketamine on “Wish to Live” and “Wish to Die” as assessed by the first two items on the SSI in patients reporting any suicidal thoughts from the SSI (n = 39). All statistics were conducted using SPSS version 21. Significance was considered at p<.05, two-tailed.

**Results**

A total of 133 patients were included in this analysis; 35 with Bipolar Disorder (19 Bipolar I and 16 Bipolar II in a depressive episode) and 98 with Major Depressive Disorder (MDD). 51% of the sample was male (n = 68), and mean age was 47.8 (SD = 12.3). At baseline (60 minutes before infusion), 61% of the sample (n = 81) reported any type of suicidal ideation (measured by a score > 0 on HAMD suicide item) and 40% (n = 53) reported a history of suicide attempts. Ideation at baseline was not associated with gender ($\chi^2 = 0.32$, p = .57), age (t(131) = −0.24, p = .81) or age of MDD/BD onset (t(124) = −0.05, p = .96) but was associated with suicide attempt history ($\chi^2 = 8.31$, df=124, p = .004).

*J Psychiatr Res. Author manuscript; available in PMC 2015 November 01.*
Correlations between changes in suicidal ideation, anxiety and depressive symptoms at 230 minutes post-ketamine infusion are presented in Table 1. The patients received ketamine in both randomized and open label studies. Changes in suicidal ideation were significantly associated with changes in depression with correlations ranging from .31 to .44. The strongest correlation of .44 (between the HAMD depression cluster and the SSI Wish To Die item) indicated that only 19% of the variance in ideation can be accounted for by depression scores. Changes in ideation were also significantly associated with anxiety with correlations ranging from .27 to .40, accounting for at most 16% of the variance. Changes in ideation in relation to changes in depression and anxiety are presented in Figure 1. In order to examine whether depression or anxiety were independently related to ideation, the HAMD anxiety cluster and the remaining HAMD items were entered into the same linear regression model to predict ideation change. The HAMD depression cluster was significantly associated with change in suicidal ideation, standardized $\beta = .24$, $p = .03$, while HAMD anxiety was not, standardized $\beta = .16$, $p = .13$.

**Linear Mixed Models**

From patients who participated in a placebo-controlled crossover study and had suicidal ideation at baseline as measured by the HAMD ($n = 57$), there was a significant reduction in suicidal ideation following ketamine compared to placebo infusion, $F_{1,586} = 42.84$, $p < .001$, but the intervention by time interaction did not reach significance, $F_{76,546} = 2.12$, $p = .050$. When controlling for the impact of ketamine on depression (HAMD without suicide items or Anxiety Somatization Score) over time in a three-way interaction, the effect of ketamine on suicidal ideation was significant, $F_{1,587} = 10.31$, $p = .001$, and the time by intervention interaction became significant, $F_{6,534} = 2.39$, $p = .03$. On post-hoc analysis, suicidal ideation significantly differed in ketamine compared to placebo at the 40 minute timepoint ($p < .001$). In a separate model, when controlling for the impact of ketamine on anxiety (HAMD Anxiety Somatization Factor Score) over time in another three way interaction, ketamine still had a significant impact on suicidal ideation, $F_{1,567} = 8.54$, $p = .004$, but the time by intervention interaction was not significant, $F_{6,535} = 1.02$, $p = .41$.

The effect of ketamine on “Wish to Live” and “Wish to Die,” as measured by the SSI, is presented in Figures 2a and 2b. This linear mixed model was limited to participants in a placebo-controlled trial and had suicidal ideation at baseline as measured by the SSI (Total SSI score > 0, $n = 39$). Ketamine infusion was associated with increased wish to live, $F_{1,393} = 53.05$, $p < .001$, and decreased wish to die, $F_{1,389} = 48.53$, $p < .001$. Neither time by intervention interaction was significant ($p > .09$). On further post-hoc analysis, the relationship of ketamine to increased wish to live and decreased wish to die persisted when controlling for depressive ($p < .01$) and anxiety symptoms ($p < .001$) across all time points.

**Discussion**

In this post-hoc analysis of 133 patients in a depressive episode, ketamine was associated with reductions in suicidal ideation independent of reductions in depressive and anxiety symptoms. Furthermore, ketamine had an impact on increased wish to live and decreased wish to die, two cognitive aspects of suicidal ideation which have been shown to predict...
later death by suicide (Brown et al., 2005a). While changes in suicidal ideation, depression and anxiety were significantly correlated, the combination of depression and anxiety symptoms only accounted for up to 19% of the variance in suicidal ideation change.

These results extend previous analyses from our group demonstrating ketamine’s ability to reduce suicidal thoughts (DiazGranados et al., 2010a; Zarate et al., 2012) and highlight the potential role of glutamatergic neurotransmission in the neurobiology of suicidal thinking. As interest in ketamine as a rapid antidepressant has grown, potential treatment response biomarkers, including PET neuroimaging (Carlson et al., 2013) and baseline clinical predictors (Ionescu et al., In Press; Niciu et al., 2014), have been evaluated to better understand its clinical and mechanistic implications (Niciu et al., 2013). With an understanding that ketamine impacts suicidal thoughts independent of improvement in depression or anxiety, comparable research can investigate biomarkers of ideation response to ketamine may illuminate potential neurobiological pathways. In preclinical studies, ketamine’s antidepressant effects are critically dependent on enhanced synaptic plasticity, which is believed to occur in response to NMDA receptor-mediated release of inhibition and concomitant “glutamate surge” from projection neurons in the prefrontal cortex and hippocampus (Duman and Aghajanian, 2012). Kavalali and Monteggia have also proposed that NMDA receptor antagonism deactivates eukaryotic elongation factor 2 (eEF2) kinase, leading to reduced eEF2 phosphorylation and increased translation of brain-derived neurotrophic factor (BDNF) (Kavalali and Monteggia, 2012). While these mechanisms remain speculative in clinical populations, we hypothesize that ketamine reduces suicidal thinking by enhancing neuroplasticity (Cornwell et al., 2012; Duncan et al., 2013).

These findings also emphasize the role of anxiety in suicidal thoughts. While the relationship between depression and suicidal thoughts is well-established, reductions in anxiety accounted for comparable reductions in ideation as depression. Results underscore the importance of evaluating both anxiety and depression when assessing suicide risk. Elevated anxiety and a history of anxiety disorder in the context of an affective disorder have been associated with imminent and long-term risk for suicidal behavior (Fawcett et al., 1990; Goldberg and Fawcett, 2012). In fact, disorders characterized by anxiety and agitation, rather than depression, have been associated with the transition from suicidal thoughts to suicidal behavior (Nock et al., 2010). Therefore, our findings reinforce the need for further investigation into the role of comorbid anxiety and depression in the development of suicidal thoughts. As outcomes in these trials were measured via self- and clinical assessments, additional psychophysiological-based measures of anxiety, including fear and anxiety-potentiated startle paradigms (Ballard et al., 2014; Schmitz and Grillon, 2012) may also be able to elucidate the relationship between suicidal thoughts and anxiety after a ketamine infusion.

There are some limitations of this study. First, this was a secondary data analysis and does not permit evaluation of causality. Second, the patients in our sample were specifically selected for current major depression, not suicidal ideation; therefore, the sample does not include acutely suicidal patients who may be seen in emergency settings. Replication of these results in a patient sample selected for higher ideation severity outside the context of a psychiatric diagnosis such as MDD or BP, e.g. a score of 4 or more on MADRS item 10 or
moderate-to-high total baseline score on the Columbia Suicide Severity Rating Scale (C-SSRS), is necessary. Such trials examining ketamine for acute suicidal ideation are currently underway (ClinicalTrials.gov identifiers: NCT01700829 and NCT01887990). Third, while patients were administered the SSI, which assesses suicidal thoughts using several items, other cognitive constructs, such as hopelessness, have been demonstrated to predict future suicide (Beck et al., 1985; Hawton et al., 2013) and may have a significant association with suicidal thoughts. A more comprehensive measure of hopelessness, such as the Beck Hopelessness Scale (Beck et al., 1974), may help elucidate how pessimism and negative perceptions for the future are affected by ketamine at antidepressant doses. Lastly, it is important to note that ketamine’s antisuicidal effects were most robust at 40 minutes after ketamine infusion, the time point associated with greatest psychotomimetic symptoms, dissociative side effects and hemodynamic changes (Luckenbaugh et al., 2014).

**Conclusion**

Reductions in suicidal ideation following ketamine infusion are related to, but also independent of, reductions in depression and anxiety. As interventions for suicidal ideation are critically needed in psychiatry, findings suggest that evaluations of ketamine can be used to further investigate the neurobiology and best treatments for suicidal individuals.

**Acknowledgments**

Funding for this work was supported by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH) (NCT00088699 and 04- M-0222) by a NARSAD Independent Investigator and by the Brain & Behavior Mood Disorders Research Award to CAZ.

**References**


• We investigated the effects of ketamine on suicidal ideation across clinical trials.
• Suicidal ideation, as independent from depression or anxiety, was evaluated.
• Depression accounted a limited amount of variance of change in suicidal thoughts.
• Ketamine had an effect on suicidal thoughts independent of depression and anxiety.
• Anxiety may be an important treatment target for suicide risk.
Figure 1.
Figure 1a and 1b. Change in ideation at 230 minutes after ketamine infusion compared to changes in depression and anxiety.
Note: Markers in graphs represent frequencies; larger markers represent more patients scoring at that value.
Figure 2.
Figures 2a and 2b. Reductions in cognitions related to suicidal ideation as measured by the SSI in placebo-controlled trials of ketamine, limited to patients any suicidal thoughts at baseline.
2a. Wish to Live
2b. Wish to Die
Table 1

Pearson Correlations between Change in Suicidal Ideation, Anxiety and Depressive Symptomatology at 230 minutes Post-Ketamine Infusion

<table>
<thead>
<tr>
<th>Change in Depression</th>
<th>Change in Suicide Ideation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAMD without Anxiety Somatization Factor Score or suicide item</td>
<td>HAMD Suicide Item</td>
</tr>
<tr>
<td></td>
<td>r</td>
</tr>
<tr>
<td>BDI without suicide item</td>
<td>.31</td>
</tr>
</tbody>
</table>

| Change in Anxiety | HAMA       | HAMD-Anxiety Somatization Factor Score | |
|                  | r | p | r | p | r | p |
| Change in Anxiety | .27 | .02 | .23 | .04 | .30 | .008 |
| HAMD-Anxiety Somatization Factor Score | .33 | <.001 | .29 | .003 | .40 | <.001 |

BDI: Beck Depression Inventory; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Rating Scale for Depression; SSI: Scale for Suicide Ideation